[
    "{\"step_by_step_thinking\": \"Enasidenib is mentioned in several documents as a treatment for acute myeloid leukemia. For instance, Document [0] states that Enasidenib was approved by the FDA for relapsed or refractory acute myeloid leukemia in people with specific mutations of the IDH2 gene. Document [1] also mentions that Enasidenib has demonstrated promising antileukemic activity by targeting IDH2 mutations. Therefore, it is clear that Enasidenib can be used for the treatment of acute myeloid leukemia.\", \"answer_choice\": \"A\"}"
]